Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Account Payables (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Change in Account Payables data on record, last reported at $8.9 million in Q3 2025.

  • For Q3 2025, Change in Account Payables rose 473.11% year-over-year to $8.9 million; the TTM value through Sep 2025 reached $10.2 million, up 892.86%, while the annual FY2024 figure was $6.3 million, 8.58% up from the prior year.
  • Change in Account Payables reached $8.9 million in Q3 2025 per GLUE's latest filing, up from -$1.1 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $13.3 million in Q4 2024 and bottomed at -$10.9 million in Q1 2025.
  • Average Change in Account Payables over 3 years is $810363.6, with a median of $306000.0 recorded in 2023.
  • Peak YoY movement for Change in Account Payables: tumbled 1756.86% in 2024, then skyrocketed 473.11% in 2025.
  • A 3-year view of Change in Account Payables shows it stood at $5.8 million in 2023, then surged by 130.72% to $13.3 million in 2024, then tumbled by 33.27% to $8.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $8.9 million in Q3 2025, -$1.1 million in Q2 2025, and -$10.9 million in Q1 2025.